Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires $33,725.00 in Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi acquired 47,500 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was acquired at an average price of $0.71 per share, for a total transaction of $33,725.00. Following the completion of the purchase, the chief executive officer now directly owns 1,214,775 shares of the company’s stock, valued at $862,490.25. This trade represents a 4.07 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Krishna Vaddi also recently made the following trade(s):

• On Monday, December 30th, Krishna Vaddi bought 10,000 shares of Prelude Therapeutics stock. The stock was acquired at an average cost of $1.20 per share, for a total transaction of $12,000.00.
• On Wednesday, December 18th, Krishna Vaddi acquired 100,000 shares of Prelude Therapeutics stock. The stock was acquired at an average cost of $0.93 per share, with a total value of $93,000.00.

Prelude Therapeutics Stock Up 9.2 %

Prelude Therapeutics stock traded up $0.07 during trading hours on Friday, hitting $0.77. The stock had a trading volume of 74,599 shares, compared to its average volume of 242,357. The company has a 50-day moving average of $0.98 and a two-hundred day moving average of $1.66. Prelude Therapeutics Incorporated has a fifty-two week low of $0.66 and a fifty-two week high of $6.80. The company has a market cap of $42.49 million, a PE ratio of -0.43 and a beta of 1.43.

Prelude Therapeutics (NASDAQ:PRLD) last issued its earnings results on Monday, March 10th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.11. The firm had revenue of $4.00 million during the quarter. As a group, analysts forecast that Prelude Therapeutics Incorporated will post -1.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Prelude Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PRLD. Massachusetts Financial Services Co. MA raised its position in Prelude Therapeutics by 5.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 549,530 shares of the company’s stock worth $1,138,000 after purchasing an additional 27,155 shares in the last quarter. Walleye Capital LLC raised its holdings in shares of Prelude Therapeutics by 446.2% in the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after buying an additional 67,946 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Prelude Therapeutics by 885.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock worth $362,000 after buying an additional 157,218 shares during the period. State Street Corp boosted its stake in Prelude Therapeutics by 35.1% in the 3rd quarter. State Street Corp now owns 286,046 shares of the company’s stock valued at $592,000 after buying an additional 74,300 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Prelude Therapeutics in the 3rd quarter valued at $100,000. 79.72% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.